Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIHARIKA B METTU

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1447427737
CMS profile
916702
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$84.58

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $50.00 1
Food and Beverage $34.58 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Ipsen Biopharmaceuticals, Inc $50.00 1
Genentech, Inc. $34.58 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIHARIKA B METTU

NPI 1447427737 · CMS profile ID 916702

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447427737?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $84.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ipsen Biopharmaceuticals, Inc $50.0011/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640616935 CMS
Genentech, Inc. $34.5801/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681160939 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.58 2
PY2022 $144.15 1
PY2023 $404.87 2
PY2025 $118.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $412,481.43 29
PY2024 Principal investigator $438,364.30 16
PY2023 Recipient $1,900.00 1
PY2023 Principal investigator $221,978.88 12
PY2022 Recipient $940.00 1
PY2022 Principal investigator $540,890.16 21
PY2021 Principal investigator $466,508.69 60
PY2020 Principal investigator $671,262.43 162
PY2019 Principal investigator $961,160.26 152

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,549.92 12/31/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 826496361
Principal investigator 1 Merck Sharp & Dohme Corporation $185,779.24 12/31/2021 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 848753315
Principal investigator 1 Merck Sharp & Dohme Corporation $73,985.08 12/31/2021 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 848753389
Principal investigator 1 Merck Sharp & Dohme Corporation $284.75 12/31/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer No dispute reported 06/30/2026 848759585
Principal investigator 1 Genentech, Inc. $5,876.90 12/17/2021 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
BACCI No dispute reported 06/30/2026 835970455
Principal investigator 1 Incyte Corporation $297.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072073
Principal investigator 1 Incyte Corporation $3,325.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072079
Principal investigator 1 Incyte Corporation $39,800.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072083
Principal investigator 1 Incyte Corporation $1,500.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072089
Principal investigator 1 Incyte Corporation $520.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072095
Principal investigator 1 Incyte Corporation $1,000.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072101
Principal investigator 1 Incyte Corporation $2,760.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072107
Principal investigator 1 Incyte Corporation $840.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072113
Principal investigator 1 Incyte Corporation $1,340.00 11/19/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831072119
Principal investigator 1 Incyte Corporation $105.80 09/15/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071879
Principal investigator 1 Incyte Corporation $297.00 09/15/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071885
Principal investigator 1 Incyte Corporation $4,661.50 09/15/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071891
Principal investigator 1 Genentech, Inc. $20,840.10 07/16/2021 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
BACCI No dispute reported 06/30/2026 835970451
Principal investigator 1 Incyte Corporation $2,436.07 06/28/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831071627
Principal investigator 1 Incyte Corporation $264.29 06/28/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 831072061
Principal investigator 1 Incyte Corporation $189.90 06/24/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071663
Principal investigator 1 AstraZeneca Pharmaceuticals LP $106,900.92 05/20/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 826484331
Principal investigator 1 Incyte Corporation $26.84 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071669
Principal investigator 1 Incyte Corporation $26.85 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071675
Principal investigator 1 Incyte Corporation $34.41 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071681
Principal investigator 1 Incyte Corporation $15.94 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071687
Principal investigator 1 Incyte Corporation $17.90 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071691
Principal investigator 1 Incyte Corporation $13.42 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071697
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071703
Principal investigator 1 Incyte Corporation $67.10 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071709
Principal investigator 1 Incyte Corporation $40.26 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071715
Principal investigator 1 Incyte Corporation $8.95 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071721
Principal investigator 1 Incyte Corporation $57.35 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071727
Principal investigator 1 Incyte Corporation $11.47 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071733
Principal investigator 1 Incyte Corporation $26.85 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071797
Principal investigator 1 Incyte Corporation $26.84 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071803
Principal investigator 1 Incyte Corporation $26.84 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071809
Principal investigator 1 Incyte Corporation $8.95 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071815
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071821
Principal investigator 1 Incyte Corporation $11.47 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071827
Principal investigator 1 Incyte Corporation $34.41 04/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071833
Principal investigator 1 Incyte Corporation $189.90 04/01/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071657
Principal investigator 1 Incyte Corporation $189.90 03/02/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071373
Principal investigator 1 Incyte Corporation $26.85 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071479
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071485
Principal investigator 1 Incyte Corporation $42.50 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071491
Principal investigator 1 Incyte Corporation $26.06 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071497
Principal investigator 1 Incyte Corporation $90.65 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071503
Principal investigator 1 Incyte Corporation $42.00 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071509
Principal investigator 1 Incyte Corporation $30.09 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071515
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071537
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071543
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071549
Principal investigator 1 Incyte Corporation $30.09 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071555
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071561
Principal investigator 1 Incyte Corporation $16.20 02/08/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831071567
Principal investigator 1 Incyte Corporation $95.00 02/01/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071605
Principal investigator 1 Incyte Corporation $189.90 01/26/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071367
Principal investigator 1 Genentech, Inc. $9,308.35 01/15/2021 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 835970443
Principal investigator 1 Incyte Corporation $95.00 01/01/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 831071593